China SXT Pharmaceuticals, Inc. (SXTC) › Cash & EquivalentsChina SXT Pharmaceuticals, Inc. (SXTC) — Cash & EquivalentsAnnual figures by fiscal year, from SEC filings.2016: $11.4K2017: $65.6K2018: $657.8K2019: $9.29M2020: $7.29M2021: $13.36M2023: $17.37M2024: $12.07M2025: $18.10M$18.10M2016Cash & Equivalents (USD)2025Fiscal YearCash & EquivalentsChange YoY2025$18.10M+49.9%2024$12.07M-30.5%2023$17.37M—2021$13.36M+83.3%2020$7.29M-21.6%2019$9.29M+1312.6%2018$657.8K+903.2%2017$65.6K+473.2%2016$11.4K—Other metrics: RevenueCost of RevenueGross ProfitOperating IncomeNet IncomeEPS (Diluted)Total AssetsTotal LiabilitiesShareholders' EquityOperating Cash FlowCapital ExpendituresShares OutstandingDividends Per Share